Drug intelligence / Profile preview

cefixime + azithromycin + lactobacillus

Development stage
Unknown
Lead developer
Scothuman Lifesciences
Modality
Small Molecules
Administration
Oral
01

Overview

afime-az-lb is a combination pharmaceutical product containing two antibiotics, cefixime and azithromycin, along with the probiotic Lactobacillus (often referred to as Lactic Acid Bacillus). Cefixime is a third-generation cephalosporin that exerts its antibacterial effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The inclusion of Lactobacillus serves as a probiotic to maintain or restore healthy intestinal microflora, thereby reducing the risk of antibiotic-associated diarrhea. This combination is typically used for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and typhoid fever. It is marketed as a branded generic product by Pharma Drugs & Chemicals under a PCD (Propaganda Cum Distribution) franchise model.

Brand names
afime-az-lb
Other names
cefixime + azithromycin + lactic acid bacillus
02

Targets

Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefixime + azithromycin + lactobacillus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefixime + azithromycin + lactobacillus.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call